EMA Authorised: Iasibon (ibandronic acid) — Pharmathen S.A.

View source ↗

Summary

EMA authorised Iasibon (ibandronic acid) for hypercalcemia, prevention of bone fractures, and cancer-related indications involving metastatic disease and breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Fractures
• Breast Cancer
• Cancer
• Hypercalcemia

Drugs mentioned

• Iasibon (ibandronic acid)

Snippet

Status: Authorised. Therapeutic area: Hypercalcemia;Fractures, Bone;Neoplasm Metastasis;Breast Neoplasms. MAH: Pharmathen S.A.. Decision date: 28/08/2024